What is the recommended first‑line therapy for an 83‑year‑old patient with hepatocellular carcinoma who is not a surgical candidate?

First-Line Systemic Therapy for an 83-Year-Old Patient with Unresectable Hepatocellular Carcinoma

Atezolizumab plus bevacizumab is the recommended first-line treatment for this 83-year-old patient with unresectable HCC, provided they have Child-Pugh class A liver function, ECOG performance status 0-1, and no contraindications to either agent—particularly no untreated esophageal varices or high bleeding risk. 1, 2

Treatment Algorithm Based on Patient Assessment

Step 1: Assess Liver Function and Performance Status

• Child-Pugh class A is mandatory for any systemic therapy; Child-Pugh B patients should receive only cautious, individualized approaches. 1
• ECOG performance status must be 0-1; patients with ECOG ≥2 derive no survival benefit from systemic therapy and should receive palliative care only. 1
• Age 83 alone is not a contraindication—functional status and comorbidities determine eligibility, not chronological age. 3

Step 2: Screen for Contraindications to Atezolizumab-Bevacizumab

Mandatory endoscopic screening within 6 months is required to assess for esophageal varices before initiating bevacizumab. 1, 2

Absolute contraindications to atezolizumab-bevacizumab include:

• Untreated or inadequately treated esophageal varices (bleeding risk with bevacizumab). 1
• Active or uncontrolled autoimmune disease (risk of immune-related adverse events with atezolizumab). 1
• Recent significant bleeding event or thrombotic disorder. 1
• Severe cardiovascular disease or uncontrolled hypertension. 1

Step 3: Choose First-Line Regimen

If NO contraindications exist:

Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV every 3 weeks is the standard of care, demonstrating superior overall survival (median 19.2 months vs 13.4 months with sorafenib; HR 0.66) and objective response rate (29.8% vs 11.4%). 1, 2

If contraindications to bevacizumab exist (e.g., untreated varices, bleeding risk):

Durvalumab 1500 mg IV plus tremelimumab 75 mg IV (single dose), then durvalumab monotherapy every 4 weeks is the preferred alternative, with median OS of 16.4 months (HR 0.78 vs sorafenib) and importantly, lower variceal bleeding risk due to absence of anti-VEGF agent. 1, 2

If contraindications to ALL immunotherapy exist (e.g., active autoimmune disease):

Lenvatinib 8 mg PO daily (for body weight <60 kg) or 12 mg PO daily (≥60 kg) is preferred over sorafenib due to non-inferior overall survival with superior progression-free survival and response rate. 1

Sorafenib 400 mg PO twice daily remains an alternative if lenvatinib is contraindicated or unavailable. 1

Single-agent durvalumab 1500 mg IV every 4 weeks may be considered when combination therapy is contraindicated, as it is non-inferior to sorafenib in overall survival. 1

Critical Safety Considerations for Elderly Patients

Atezolizumab-Bevacizumab Specific Precautions:

• Variceal screening and prophylaxis must be completed before cycle 1; patients with portal hypertension require endoscopy within 6 months and adequate variceal treatment. 1, 2
• Monitor for immune-related adverse events (hepatitis, colitis, pneumonitis, endocrinopathies) requiring high-dose corticosteroids in approximately 20% of patients. 2
• Assess cardiovascular risk carefully in elderly patients, as bevacizumab increases thrombotic and bleeding complications. 1

Durvalumab-Tremelimumab Specific Precautions:

• Immune-related adverse events requiring high-dose glucocorticoids occur in 20.1% of patients, which may be particularly problematic in elderly individuals with comorbidities. 2
• Lower bleeding risk compared to atezolizumab-bevacizumab makes this regimen preferable when varices cannot be adequately treated. 1, 2

TKI (Lenvatinib/Sorafenib) Specific Precautions:

• Dose reductions are frequently required in elderly patients due to toxicity (hypertension, diarrhea, hand-foot syndrome, fatigue). 1
• Renal function monitoring is essential, as elderly patients are more susceptible to TKI-related renal impairment. 1

Common Pitfalls to Avoid

Do not initiate atezolizumab-bevacizumab without endoscopic variceal assessment—this is the most common and dangerous error, as variceal bleeding can be fatal. 1, 2

Do not offer systemic therapy to patients with ECOG ≥2 or Child-Pugh B8-9/C—these patients should receive palliative care only, as systemic therapy provides no survival benefit and worsens quality of life. 1, 4

Do not assume age 83 is a contraindication—functional status (ECOG, Child-Pugh) determines eligibility, not chronological age; well-selected elderly patients tolerate systemic therapy similarly to younger patients. 3

Do not use tamoxifen—it has been definitively shown to be ineffective and should be regarded as placebo therapy. 4

Do not combine TACE with systemic therapy outside clinical trials—there is insufficient evidence to recommend this combination despite promising early signals. 1

Second-Line Planning

After progression on atezolizumab-bevacizumab, switch to a tyrosine kinase inhibitor (sorafenib, lenvatinib, or cabozantinib) or ramucirumab (if AFP ≥400 ng/mL), provided the patient remains Child-Pugh A and ECOG 0-1. 1, 2

After progression on durvalumab-tremelimumab, TKIs are reasonable based on mechanism of action. 1, 2

After progression on first-line TKI monotherapy, regorafenib (if sorafenib-tolerant), cabozantinib, ramucirumab (AFP ≥400 ng/mL), or immunotherapy combinations may be considered. 1

Continuing immunotherapy in second-line after first-line TKI plus PD-1 inhibitor failure confers no additional efficacy—alternative strategies should be explored. 5